When the FDA’s Pharmacy Compounding Advisory Committee meets July 23-24, it will consider whether seven peptides should be added to the Section 503A Bulks List. The committee’s recommendation could shape future FDA policy on pharmacy compounding.
The discussion will likely focus on access and patient care. It should also include another question: Where will the active ingredients come from?
Recent reporting has highlighted China’s growing role in peptide manufacturing. That comes as the United States continues to reduce its dependence on Chinese pharmaceutical and chemical supply chains, particularly those connected to the fentanyl crisis.
These are separate issues, but they raise an important policy question. If more peptides become available for routine compounding, could demand increasingly be met through overseas manufacturers?
The FDA has repeatedly warned consumers about unapproved compounded products, including compounded GLP-1 drugs. The agency has cited concerns about counterfeit products, dosing errors, ingredients that differ from what is advertised, and products that have not been reviewed for safety, effectiveness, or quality.
Supply chain security is also part of the conversation. Provisional CDC data show synthetic opioids, primarily fentanyl, claimed more than 38,000 American lives in 2025.
Policymakers have spent years trying to reduce reliance on Chinese chemical supply chains. As peptide manufacturing expands, they should understand whether new dependencies are emerging.
The FDA’s review presents an opportunity to ask a few straightforward questions:
- Where do compounders source the active pharmaceutical ingredients used in peptides?
- How much of the global peptide supply chain is concentrated in China?
- What safeguards ensure the quality and traceability of imported ingredients?
- Should the United States place greater emphasis on domestic pharmaceutical manufacturing as demand for peptides grows?
Those questions extend beyond healthcare. They touch on economic security, supply chain resilience, and America’s ability to manufacture critical products at home. Whether the issue is pharmaceuticals, energy, or advanced manufacturing, policymakers should understand the long-term consequences of creating new dependencies on foreign supply chains.
The FDA’s review is an opportunity to have that conversation before policy moves forward.